Viracta Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Viracta Therapeutics

13/05/2021 01:41

* Viracta Therapeutics Inc  VIRX.OQ  reported quarterly adjusted
earnings of 35 cents​​ per share for the quarter ended in March.
The mean expectation of four analysts for the quarter was for a
loss of 21 cents per share.
* Reported revenue was zero​;  analysts expected $4.50 million. 
* Viracta Therapeutics Inc's reported EPS for the quarter was a
loss of $5.22​.
* The mean earnings estimate of analysts had risen by
about 79.3% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Viracta Therapeutics Inc shares had fallen by 4.2% this
quarter and gained 27.2% so far this year.
* The company reported a quarterly loss of $79.23 million.
* Wall Street's median 12-month price target for Viracta
Therapeutics Inc is $35.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 13 at 12:41 a.m. GMT.
​All figures in US dollars